scholarly journals “Catechol-O-methyltransferase gene Val158Met polymorphism and prostate cancersusceptibility”

2020 ◽  
Author(s):  
Pradeep Kumar ◽  
Vandana Rai
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Genetic Model ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Case Control ◽  
Case Control Studies ◽  
Comt Val158met ◽  
Val158met Polymorphism ◽  
Allele Contrast

AbstractProstate cancer is one of the most common and a serious malignancy of males and it is well reported that estrogen plays a pivotal role in prostate carcinogenesis. Catechol-O - methyltransferase (COMT) catalyzes the inactivation of estrogens. Several studies have investigated the association of COMT gene Val158Metpolymorphism with prostate cancer, but results were inconsistent and inconclusive. Hence, to assess this association, we performed a meta-analysis of all published case-control studies. Pubmed, Springer link, Google Scholar, Elsevier and Springer link databases were searched for case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) was used as association measure. Statistical analysis was performed with the software program MIX and MetaAnalyst. In the current meta-analysis, 11 case control studies with 3381 prostate cancer cases and 3,276 healthy controls were considered. The results indicated no significant association between COMT Val158Met polymorphism and prostate cancer risk using allele contrast, co-dominant and homozygote models (allele contrast: OR= 0.92; 95% CI 0.85 to 0.98=; p= 0.02; co-dominant: OR=0.81; 95% CI= 0.85 to1.07; p= 0.46; homozygote: OR= 0.81; 95% CI= 0.70 to 0.95, p= 0.008), but showed significant association with dominant and recessive models (dominant: OR 1.18=; 95% CI= 1.03 to1.34; p= 0.01; recessive: OR= 1.54; 95% CI= 1.1 to 2.07; p = 0.003). In subgroup analysis meta-analysis using recessive genetic model showed significant association between COMT Val 158Met polymorphism and prostate cancer risk in both Asian and Caucasian populations. In conclusion, results of present meta-analysis supports that the COMT Val158Met polymorphism is risk factor for prostate cancer.

No Association Between COMT Val158Met Polymorphism and Prostate Cancer Risk: A Meta-Analysis

2013 ◽  
Vol 17 (1) ◽  
pp. 78-84 ◽  
Author(s):  
Li-wei Zou ◽  
Xiao-juan Xu ◽  
Ting Liu ◽  
Han-yong Wang ◽  
Wen-jing Fan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Comt Val158met ◽  
Val158met Polymorphism

scholarly journals Association of GSTM1 Null Allele with Prostate Cancer Risk: Evidence from 36 Case-Control Studies

PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e46982 ◽  
Author(s):  
Bingbing Wei ◽  
Zhuoqun Xu ◽  
You Zhou ◽  
Jun Ruan ◽  
Huan Cheng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Null Allele ◽  
Prostate Cancer Risk ◽  
Case Control ◽  
Case Control Studies

The RTK/ERK pathway is associated with prostate cancer risk on the SNP level: A pooled analysis of 41 sets of data from case–control studies

Gene ◽  
2014 ◽  
Vol 534 (2) ◽  
pp. 286-297 ◽  
Author(s):  
Yang Chen ◽  
Tianyu Li ◽  
Xiaoqiang Yu ◽  
Jianfeng Xu ◽  
Jianling Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Pooled Analysis ◽  
Case Control ◽  
Erk Pathway ◽  
Case Control Studies

scholarly journals Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies

2007 ◽  
Vol 29 (3) ◽  
pp. 568-572 ◽  
Author(s):  
K. N. Danforth ◽  
R. B. Hayes ◽  
C. Rodriguez ◽  
K. Yu ◽  
L. C. Sakoda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Case Control ◽  
Case Control Studies ◽  
Polymorphic Variants ◽  
Nested Case Control

scholarly journals Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis

2008 ◽  
Vol 17 (9) ◽  
pp. 2325-2336 ◽  
Author(s):  
Luisa Zuccolo ◽  
Ross Harris ◽  
David Gunnell ◽  
Steven Oliver ◽  
Jane Athene Lane ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Case Control ◽  
Nested Case Control ◽  
Control Study

Significant Association of Catechol-O-Methyltransferase Val158Met Polymorphism with Bladder Cancer Instead of Prostate and Kidney Cancer

2016 ◽  
Vol 31 (2) ◽  
pp. 110-117 ◽  
Author(s):  
Yang Chen ◽  
Xiaoxiang Yu ◽  
Tianyu Li ◽  
Haibiao Yan ◽  
Zengnan Mo
Keyword(s):  
Prostate Cancer ◽  
Bladder Cancer ◽  
Cancer Risk ◽  
Kidney Cancer ◽  
Cancer Susceptibility ◽  
Prostate Cancer Risk ◽  
Comt Val158met ◽  
Val158met Polymorphism ◽  
Urological Cancers ◽  
Codominant Model

Background Urological cancers occur worldwide. Many factors, among which the catechol-O-methyltransferase (COMT) Val158Met polymorphism, are said to be associated with the cancer risk. We conducted a meta-analysis to investigate the association between urological cancer susceptibility and COMT Val158Met in different genetic models. Methods This study was based on material obtained from the PubMed, HuGENet and Embase databases. Four models including dominant (AA + AG vs. GG), recessive (AA vs. AG + GG), codominant (AA vs. AG, AA vs. GG) and per-allele analysis (A vs. G) were applied. Odds ratios (OR) and the corresponding 95% confidence intervals (CI) were used to evaluate the power of the associations. Results Fourteen eligible studies comprising 3,285 cases and 3,594 controls were included. Although we could not detect a positive function of the COMT Val158Met polymorphism in urological cancers, the polymorphism might be significantly associated with bladder cancer risk (dominant model [AA + AG vs. GG]: OR = 0.736, 95% CI = 0.586-0.925, I2 = 0.00%; recessive model [AA vs. AG + GG]: OR = 0.822, 95%CI = 0.653-1.035, I2 = 6.30%; codominant model [AA vs. AG]: OR = 0.908, 95% CI = 0.710-1.161, I2 = 0.00%; codominant model [AA vs. GG]: OR = 0.693, 95% CI = 0.524-0.917, I2 = 30.20%; allele analysis [A vs. G]: OR = 0.826, 95%CI = 0.717-0.951, I2 = 30.20%). The same significant associations were not found for kidney cancer and prostate cancer risk in different ethnicities. There also seemed to be no distinct effect of the polymorphism on benign prostatic hyperplasia. Conclusions We suggest that bladder cancer but not prostate cancer and kidney cancer could be significantly associated with the Val158Met polymorphism. Interaction of COMT genetic and related environmental factors for urological cancers should not be ignored in future.

scholarly journals Marital Status and Prostate Cancer Incidence: A Pooled Analysis of 12 Case-Control Studies From the PRACTICAL Consortium

2021 ◽  
Author(s):  
Charlotte Salmon ◽  
Lixin Song ◽  
Kenneth R Muir ◽  
Nora Pashayan ◽  
Alison M Dunning ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Social Support ◽  
Cancer Risk ◽  
Marital Status ◽  
Prostate Cancer Risk ◽  
Case Control ◽  
Cancer Prognosis ◽  
Low Grade ◽  
High Grade ◽  
Case Control Studies

Abstract While being in a committed relationship is associated with a better prostate cancer prognosis, little is known about how marital status relates to its incidence. Social support provided by marriage/relationship could promote a healthy lifestyle and an increased healthcare seeking behavior.We investigated the association between marital status and prostate cancer risk using data from the PRACTICAL Consortium. Pooled analyses were conducted combining 12 case-control studies based on histologically-confirmed incident prostate cancers and controls with information on marital status prior to diagnosis/interview. Marital status was categorized as married/partner, separated/divorced, single, or widowed. Tumours with Gleason scores ≥8 defined high-grade cancers, and low-grade otherwise. NCI-SEER’s summary stages (local, regional, distant) indicated the extent of the cancer. Logistic regression was used to derive odds ratios (ORs) and 95% confidence intervals (CI) for the association between marital status and prostate cancer risk, adjusting for potential confounders. Overall, 14,760 cases and 12,019 controls contributed to analyses. Compared to men who were married/with a partner, widowed men had an OR of 1.19 (95%CI 1.03-1.35) of prostate cancer, with little difference between low- and high-grade tumours. Risk estimates among widowers were 1.14 (95%CI 0.97-1.34) for local, 1.53 (95%CI 1.22-1.92) for regional, and 1.56 (95%CI 1.05-2.32) for distant stage tumours. Single men had elevated risks of high-grade cancers. Our findings highlight elevated risks of incident prostate cancer among widowers, more often characterized by tumours that had spread beyond the prostate at the time of diagnosis. Social support interventions and closer medical follow-up in this sub-population are warranted.

Sign in / Sign up

Export Citation Format

Share Document